Abamectin

Summary

Abamectin (CHEMBL3215298) is a phase-3 clinical-stage unknown; indicated across 1 condition including malaria.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 1 condition
• Clinical trials: 6
• Chemistry: 1732.1 Da · C95H142O28

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3215298
Name	Abamectin
Type	Unknown
Max phase	3
FDA approved	no
PubChem CID	9920327
Molecular formula	C95H142O28
Molecular weight	1732.1
InChIKey	IBSREHMXUMOFBB-JFUDTMANSA-N

SMILES: CC[C@H](C)[C@@H]1[C@H](C=C[C@@]2(O1)C[C@@H]3C[C@H](O2)C/C=C(/[C@H]([C@H](/C=C/C=C/4\CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)\C)C.C[C@H]1/C=C/C=C/2\CO[C@H]3[C@@]2([C@@H](C=C([C@H]3O)C)C(=O)O[C@H]4C[C@@H](C/C=C(/[C@H]1O[C@H]5C[C@@H]([C@H]([C@@H](O5)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O)OC)OC)\C)O[C@]7(C4)C=C[C@@H]([C@H](O7)C(C)C)C)O

IUPAC name: (1’R,2R,3S,4’S,6S,8’R,10’E,12’S,13’S,14’E,16’E,20’R,21’R,24’S)-2-[(2S)-butan-2-yl]-21’,24’-dihydroxy-12’-[(2R,4S,5S,6S)-5-[(2S,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-4-methoxy-6-methyloxan-2-yl]oxy-3,11’,13’,22’-tetramethylspiro[2,3-dihydropyran-6,6’-3,7,19-trioxatetracyclo[15.6.1.14,8.020,24]pentacosa-10,14,16,22-tetraene]-2’-one;(1’R,2R,3S,4’S,6S,8’R,10’E,12’S,13’S,14’E,16’E,20’R,21’R,24’S)-21’,24’-dihydroxy-12’-[(2R,4S,5S,6S)-5-[(2S,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-4-methoxy-6-methyloxan-2-yl]oxy-3,11’,13’,22’-tetramethyl-2-propan-2-ylspiro[2,3-dihydropyran-6,6’-3,7,19-trioxatetracyclo[15.6.1.14,8.020,24]pentacosa-10,14,16,22-tetraene]-2’-one

Also known as: Abamectin, Abamectina, Abamectine, Agri-mek, Avermectin b1, Avid, Avomec, Bovitin, Doratect, Duomectin, Duotin, Endecto

Patent coverage: 14,675 distinct patent families (37,867 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: D(1A) dopamine receptor, Adenosine receptor A3, Glycine receptor.

Bioactivity

ChEMBL activities: 6 potent at pChembl ≥ 5 of 6 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P07727	7.12	Ki	75	nM	CHEMBL_ACT_7626464
P07727	6.88	IC50	132	nM	CHEMBL_ACT_7626463
ADORA3	6.31	Ki	492	nM	CHEMBL_ACT_7626354
ADORA3	6.06	IC50	870	nM	CHEMBL_ACT_7626353
DRD1	5.51	Ki	3060	nM	CHEMBL_ACT_7626432
DRD1	5.21	IC50	6119	nM	CHEMBL_ACT_7626431

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
malaria	3	MONDO:0005136	EFO:0001068

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
Not specified	5
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02533336	PHASE3	TERMINATED	The Effectiveness of Non-Pyrethroid Insecticide-Treated Durable Wall Liners as a Method for Malaria Control in Endemic Rural Tanzania
NCT02548624	Not specified	WITHDRAWN	An Assessment of the Zephyr BioPatch and Its Ability to Monitor Patient Position
NCT02570906	Not specified	COMPLETED	Performance Assessment of a Remote Patient Monitoring Device
NCT03059433	Not specified	COMPLETED	Randomized Trial of a Social Networks Intervention
NCT04517916	Not specified	COMPLETED	Zephyr Etude Post-Inscription (French Registry)
NCT04559464	Not specified	COMPLETED	Fissure Closure With the AeriSeal System for CONVERTing Collateral Ventilation Status (CONVERT)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).